Pfizer Recalls Nurtec ODT Prescription Drugs Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning

Nurtec® ODT (rimegepant) orally disintegrating tablets, 75mg 8-Unit Dose blister pack

Date of Recall

2023-03-16

CPSC Release Number

23-154

Manufactured In

United States

Units

About 4.2 million

Manufacturer

Biohaven Pharmaceuticals Inc., of New Haven, Conn. and Pfizer Inc., of New York

Sold By

Pharmacies nationwide as a prescribed medicine from December 2021 through March 2023. The prices of the product varied based on health insurance terms and other factors.

Problem/Hazard

The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children.

Injuries/Incidents

None reported

Description

This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets. The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, NDC number and expiration date. The dosage strength and expiration date are printed or stamped on the blister card.

The recall includes the following:

Product Description	NDC Number	Expiration Date
Nurtec® ODT (rimegepant) 75mg 8-Unit Dose blister pack	72618-3000-2	All dates through 6/2026

Remedy

New Instructions

No comments have been posted.
Be the first to add a comment!